PATENT CLAIM ANALYSIS

Application Number: 16044862
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "183000"]

Abstract:
Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

Claim (Index 25):
The method of  claim 1  further comprising administering to the patient a therapeutic agent selected from 5-FU, docetaxel, eribulin, gemcitabine, cobimetinib, ipatasertib, paclitaxel, tamoxifen, fulvestrant, GDC-0810, dexamethasone, palbociclib, bevacizumab, pertuzumab, trastuzumab emtansine, trastuzumab and letrozole.

Metadata:
- Claim Count in Document: 63.0
- Percentile: 95.0
- Lexical Diversity: 1.45902
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15258175', '14930929', '12890812', '13477587', '13424500']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8049009012788134
- 35 USC 102 Novelty (BERT): 0.6051649653852469
- Combined Prediction Score: 0.7849273076894567
- Mean Citation Score: 505.825478
- Max Citation Score: 671.0267
- Similarity Product: 432.29681627515566

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test